Impact of Vaccine Schedule Change on Pertussis Epidemiology in France: A Modelling and Serological Study

2021 ◽  
Author(s):  
Juliette Paireau ◽  
Sophie Guillot ◽  
Fatima Aït El Belghiti ◽  
Soraya Matczak ◽  
Sabine Trombert-Paolantoni ◽  
...  
Keyword(s):  
Serological Study ◽  
Vaccine Schedule ◽  
Schedule Change ◽  
Pertussis Epidemiology

Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study

2021 ◽  
Author(s):  
Juliette Paireau ◽  
Sophie Guillot ◽  
Fatima Aït El Belghiti ◽  
Soraya Matczak ◽  
Sabine Trombert-Paolantoni ◽  
...  
Keyword(s):  
Serological Study ◽  
Vaccine Schedule ◽  
Pertussis Epidemiology

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age

Vaccine ◽  
2018 ◽  
Vol 36 (45) ◽  
pp. 6688-6694 ◽  
Author(s):  
Marilou Kiely ◽  
Marie-Noëlle Billard ◽  
Eveline Toth ◽  
Joseline G. Zafack ◽  
Monique Landry ◽  
...  
Keyword(s):  
Vaccine Schedule ◽  
Local Reactions ◽  
Large Local Reactions ◽  
Schedule Change

The utility of seroepidemiology for tracking trends in pertussis infection

2009 ◽  
Vol 138 (3) ◽  
pp. 426-433 ◽  
Author(s):  
H. E. QUINN ◽  
P. B. McINTYRE ◽  
J. L. BACKHOUSE ◽  
H. F. GIDDING ◽  
J. BROTHERTON ◽  
...  
Keyword(s):  
Population Based ◽  
Age Group ◽  
Igg Antibody ◽  
Pertussis Infection ◽  
Population Prevalence ◽  
Antibody Assays ◽  
Schedule Change ◽  
Notification Data ◽  
Different Levels ◽  
Pertussis Epidemiology

SUMMARYComparing pertussis epidemiology over time and between countries is confounded by differences in diagnostic and notification practices. Standardized serological methods applied to population-based samples enhance comparability. Population prevalence of different levels of pertussis toxin IgG (PT IgG) antibody, measured by standardized methods, were compared by age group and region of Australia between 1997/1998 and 2002. The proportion of 5- to 9-year-olds with presumptive recent pertussis infection (based on IgG levels ⩾62·5 ELISA units/ml) significantly decreased in 2002, consistent with notification data for the same period and improved uptake of booster vaccines following the schedule change from whole-cell to acellular vaccine. In contrast, recent presumptive infection significantly increased in adults aged 35–49 years. Population-based serosurveillance using standardized PT IgG antibody assays has the potential to aid interpretation of trends in pertussis incidence in relation to vaccine programmes and between countries.

A Serological Study on Bovine Leukemia Virus Infection in Ten Provinces of Iran between 2010 and 2012

2012 ◽  
Vol 6 (3) ◽  
pp. 1-7 ◽  
Author(s):  
M Kazemimanesh ◽  
O Madadgar ◽  
MR Mahzoonieh ◽  
T Zahraei-Salehi ◽  
F Steinbach ◽  
...  
Keyword(s):  
Virus Infection ◽  
Bovine Leukemia Virus ◽  
Leukemia Virus ◽  
Bovine Leukemia Virus Infection ◽  
Serological Study

scholarly journals MYCOLOGICAL AND SEROLOGICAL STUDY OF PULMONARY ASPERGILLOSIS IN CENTRAL INDIA

2002 ◽  
Vol 20 (3) ◽  
pp. 141-144
Author(s):  
AM Kurhade ◽  
JM Deshmukh ◽  
RP Fule ◽  
C Chande ◽  
S Akulwar
Keyword(s):  
Central India ◽  
Serological Study ◽  
Pulmonary Aspergillosis

scholarly journals A Study of Varicella Seroprevalence in a Pediatric and Adolescent Population in Florence (Italy). Natural Infection and Vaccination-Acquired Immunization

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 152
Author(s):  
Beatrice Zanella ◽  
Angela Bechini ◽  
Benedetta Bonito ◽  
Marco Del Riccio ◽  
Alessandra Ninci ◽  
...  
Keyword(s):  
Natural Infection ◽  
Age Groups ◽  
Varicella Vaccination ◽  
Age Group ◽  
Disease Notification ◽  
Test Elisa ◽  
Vaccine Schedule ◽  
Almost All ◽  
Vaccination Campaigns ◽  
Dose Vaccine

Background: Varicella is a well-known infectious disease that can have severe complications, also in young children. The Universal Varicella Vaccination (UVV) program was introduced in Tuscany (Italy) in 2003, with a two-dose vaccine schedule given to children between their 13th and 15th month, and at 5–6 years old, as a monovalent for varicella (V) or tetravalent (measles, mumps, rubella and varicella (MMRV)) formulation. Although varicella notifications have dramatically fallen in the last two decades, varicella disease underreporting remains a challenge. Methods: A qualitative immunoenzymatic test (ELISA) was used to measure the presence of anti-varicella antibodies in 165 sera of subjects aged 1–18 years residing in the province of Florence (Italy). Information regarding the anamnestic and vaccination status (including disease notification) was also collected. Results: Our study showed an overall varicella seropositivity of 75.8% (reaching the maximum at 96.3% in the 15–18 years age group). We found that varicella disease notification had been recorded for only 7/165 subjects; however, since 42/165 recalled having had the disease, we can hypothesize that some of them must have been underreported. Furthermore, our study showed that the presence of antibodies after the varicella vaccination remained over time, lasting up to 12 years. Conclusions: Although varicella seroprevalence is <95% in almost all our age groups (except for the 15–18 years age group), our data are encouraging and reflect the success of the introduction of the UVV program and the vaccination campaigns promoted in the Tuscany region.

scholarly journals 1400. Physician Attitudes towards Combination Vaccine Use in Infants up to 24 months of age in the United States (US)

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S708-S709
Author(s):  
Ya-Ting Chen ◽  
Xinyi Ng ◽  
Tanaz Petigara ◽  
Jyoti Aggarwal ◽  
Jenna Bhaloo ◽  
...  
Keyword(s):  
Research Study ◽  
Scientific Research ◽  
Physician Attitudes ◽  
Combination Vaccine ◽  
Hexavalent Vaccine ◽  
Family Practitioners ◽  
Study Investigator ◽  
Vaccine Schedule ◽  
Combination Vaccines ◽  
Number Of Injections

Abstract Background Combination vaccines reduce the number of injections and improve the timeliness of vaccination coverage. US Advisory Committee on Immunization Practices (ACIP) recommendations state that combination vaccines are generally preferred over equivalent individual component vaccines. Healthcare providers strongly influence parental decisions about vaccination. We sought a contemporary understanding of physician’s attitudes towards combination vaccine use in infants. Methods We conducted an online survey of US physicians (70 pediatricians and 30 family practitioners) who administer vaccines to infants aged 0-24 months and spend at least 2 days a week providing patient care. Information was collected on attitudes towards combination vaccines and factors that influence the choice of combination vaccine used in clinical practice. Descriptive analyses were performed. Results Physicians (mean age=50.2 years, range 30.0-70.0; 66% white; 37% women) reported a median of 4 injections (range 2-9) as the maximum that parents would accept at a single visit, and 71% routinely explained what combination vaccines are to parents. When deciding which pentavalent vaccine to use, physicians considered how the brand fits into the current vaccine schedule (71%); upfront purchase costs (64%); and availability as a prefilled syringe (61%). The main reasons for using combination vaccines were to reduce the number of injections (96%); ensure the infant is up-to-date with vaccinations (86%); and reduce the pain that the infant experiences with multiple injections (68%). More than half reported that their institution or practice has a program to incentivize infant vaccination according to schedule. If a hexavalent vaccine-based schedule was available, 76% of physicians said they would choose it over their current schedule comprising pentavalent or equivalent component vaccines. Conclusion Choice of pentavalent combination vaccine among pediatricians and family practitioners was largely dependent on convenience and cost-related factors. Over three-quarters would be inclined to use a hexavalent vaccine schedule if available. Disclosures Ya-Ting Chen, PhD, Merck & Co., Inc. (Employee, Shareholder) Xinyi Ng, PhD, Merck & Co., Inc. (Consultant) Tanaz Petigara, PhD, Merck & Co., Inc. (Employee, Shareholder) Jyoti Aggarwal, MHS, Merck & Co., Inc. (Consultant) Jenna Bhaloo, MPH, Merck & Co., Inc. (Consultant) Michelle Goveia, MD, Merck & Co., Inc (Employee, Shareholder) David Johnson, MD, MPH, Sanofi Pasteur (Employee, Shareholder) Gary S. Marshall, MD, GlaxoSmithKline (Consultant, Scientific Research Study Investigator)Merck (Consultant, Scientific Research Study Investigator)Pfizer (Consultant, Scientific Research Study Investigator)Sanofi Pasteur (Consultant, Grant/Research Support, Scientific Research Study Investigator, Honorarium for conference lecture)Seqirus (Consultant, Scientific Research Study Investigator)

Sign in / Sign up

Export Citation Format

Share Document